Article Per Year (5 Year)
p-Index From 2020 - 2025
0.751
P-Index
This Author published in this journals
All Journal Indonesian Journal of Cancer Indonesian Journal of Cancer Jurnal Penyakit Dalam Indonesia
HILMAN TADJOEDIN, HILMAN
Divisi Hemotologi-Onkologi Medik, Departemen Ilmu Penyakit Dalam, Fakultas Kedokteran Universitas Indonesia/RSUPN Dr. Cipto Mangunkusumo, Jakarta
Biochemistry, Genetics & Molecular Biology Health Professions Immunology & microbiology Medicine & Pharmacology Public Health

Published : 9 Documents Claim Missing Document
Claim Missing Document
Check
Articles

Found 9 Documents
Search

 1 
Neoadjuvant Chemotherapy for Early Stage Cervical Cancer TADJOEDIN, HILMAN
Indonesian Journal of Cancer Vol 4, No 5 (2010): Workshops 2010
Publisher : "Dharmais" Cancer Center Hospital

Show Abstract | Download Original | Original Source | Check in Google Scholar

Abstract

https://www.scribd.com/doc/43601513/Neoadjuvant-Chemotherapy-for-Early-Stage-Cervical-Cancer
Efficacy and Safety of In-Asia-Manufactured rhG-CSF 300 mcg As Primary Prophylaxis for Prevention of CHOP Chemotherapy-induced Severe Neutropenia in Elderly Patients with Lymphoma Non-Hodgkin Reksodiputro, Harryanto; Djoerban, Zubairi; Tambunan, Karmel L.; Sudoyo, Aru W.; Widjanarko, Abidin; Atmakusuma, Djumhana; Syafei, Syafrizal; Prayogo, Nugroho; Hukom, Ronald; Ranuhardy, Dody; Jack, Zakifman; Harsal, Asrul; -, Noorwati S; Karsono, Bambang; Effendi, Shufrie; Tadjoedin, Hilman
Indonesian Journal of Cancer Vol 3, No 1 (2009): Jan - Mar 2009
Publisher : "Dharmais" Cancer Center Hospital

Show Abstract | Download Original | Original Source | Check in Google Scholar | Full PDF (790.74 KB)

Abstract

Penelitian open-label, non-komparatif ini dilakukan untuk mengevaluasi efektivitas dan keamanan recombinant human G-CSF produksi Asia sebagai profilaksis primer dalam pencegahan neutropenia derajat berat pada pasien usia lanjut (>60 tahun) dengan limfoma non-Hodgkin (LNH) derajat sedang dan lanjut (stadium II,III,IV) yang mendapat terapi CHOP (siklofosfamid, doksorubisin, vinkristin). Profilaksis primer recombinant human G-CSF (rhG-CSF) produksi Asia dapat mengurangi median durasi neutropenia derajat 4 pada siklus sitostatistika ke-1 dan ke-2 menjadi tiga hari, sementara median durasi neutropenia derajat 3 pada siklus sitostistika ke-1 menjadi dua hari dan pada siklus sitostatistika ke-2 menjadi dua setengah hari, dari median durasi neutropenia grade 4 dan grade 3 tanpa G-CSF, yaitu empat dan lima hari berurutan. Febrile neutropenia ditemukan pada 7 pasien yang mendapat rhG-CSF produksi Asia (24.1%), lebih rendah jika dibandingkan studi tanpa rhG-CFS (31.3-34% FN). Tiga pasien mendapat rhG-CSF produksi Asia (10,3%) dirawat inap akibat febrile neutropenia, lebih rendah jika dibandingkan rawat inap pada studi tanpa rhG-CSF (24-28%). Kejadian yang tidak diinginkan terbanyak adalah mual dan muntah yang terjadi pada 9 (31%) pasien. Sebagai kesimpulan, penggunaan rhG-CSF produksi Asia untuk profilaksis primer pada pasien LNH usia lanjut yang mendapat regimen CHOP dapat mengurangi durasi neutropenia, mengurangi kejadian febrile neutropenia, dan angka rawat inap akibat febrile neutropenia.Kata kunci : Efektivitas, keamanan, G-CSF, LNH pada usia lanjut
Preliminary Report: Clinical Characteristic, Hematologic Response and Gene Mutation of Patients with Chronic Phase Chronic Myeloid Leukemia (CML) to Imatinib at Cipto Mangunkusumo National Hospital (RSUPN CM) Reksodiputro, Arif Harryanto; Tadjoedin, Hilman; Rinaldi, Ikhwan
Indonesian Journal of Cancer Vol 5, No 4 (2011): Oct - Dec 2011
Publisher : "Dharmais" Cancer Center Hospital

Show Abstract | Download Original | Original Source | Check in Google Scholar | Full PDF (187.199 KB)

Abstract

Leukemia Granulositik Kronik (LGK) disebabkan oleh gen BCR-Abl domain tyrosin kinase, produk dari kromosom Philadelphia. Imatinib mesylate merupakan inhibitor selektif terhadap kinase tersebut. Di Indonesia, data mengenai karakteristik pasien LGK fase kronik, respons hematologi terhadap imatinib, dan mutasi gen masih jarang ditemukan. Metode dan desain: studi potong lintang ini menggunakan data rekam medik pasien yang didiagnosis sebagai LGK fase kronik dengan BCR-ABL positif yang berobat ke Poliklinik Teratai Departemen Ilmu Penyakit Dalam Rumah Sakit Cipto Mangunkusumo selama Januari – Desember 2009.Hasil: dalam periode 1 tahun studi, peneliti mengikutsertakan 20 pasien LGK fase kronik yang memiliki BCR-ABL positif dengan median umur 36 tahun (13-62 tahun). Pasien laki-laki lebih banyak dibandingkan dengan perempuan (12 vs 7) dengan rasio 1,7: 1. Sebanyak tujuh pasien (36,8%) berasal dari suku Jawa. Dilaporkan juga karakteristik pasien adalah 15 orang berada pada fase kronik (78,9%); 3 pasien berada pada fase akselerasi (15,8%) sementara 1 pasien mengalami krisis blast (5,3%); 12 pasien (63,2%) ditemui adanya splenomegali; dan 5 dari 11 pasien dilaporkan memiliki skor Sokal yang rendah. Berdasarkan hasil laboratorium didapati nilai median hemoglobin 9,9 g/dL (5-14 g/dL); leukosit 73.000/uL (4.100-332.000/uL) dan nilai median trombosit 481.000/uL (263.000/uL-1.116.000/uL); nilai median kadar basofil di darah perifer 1% (1-10%) dengan nilai median sel blast di perifer adalah 1% (0-22%). Selama studi, respons hematologik komplet dalam 3 bulan dicapai oleh 10 dari 19 pasien (52,6%), termasuk di antaranya 1 pasien yang mengalami fase akselerasi dan 1 pasien yang lain mengalami krisis blast. Sebanyak 18 pasien (94,7%) telah diobati dengan hydrea sebelum mendapat terapi Imatinib, sementara 1 pasien (5,3%) tidak pernah mendapatkan pengobatan apapun sebelumnya.Kesimpulan: didapati nilai median usia pasien LGK fase kronik adalah 36 tahun, sebagian besar adalah laki-laki. Sebanyak enam puluh tiga persen pasien memiliki splenomegali. Dilaporkan juga nilai median leukosit adalah 73.000/uL (4.100-332.000/uL) dengan nilai median sel blast di darah perifer sebanyak 1% (0-22%). Respons hematologik komplet dalam 3 bulan dicapai oleh 52,6% pasien.Kata kunci: LGK fase kronik, imatinib, respons hematologik, mutasi.
Multiple Myeloma in Indonesia Tadjoedin, Hilman; Reksodiputro, Arry Harryanto; Toruan, Toman
Indonesian Journal of Cancer Vol 5, No 2 (2011): Apr - Jun 2011
Publisher : "Dharmais" Cancer Center Hospital

Show Abstract | Download Original | Original Source | Check in Google Scholar | Full PDF (75.156 KB)

Abstract

Tujuan: Melihat karakteristik klinis pasien mieloma multipel di Indonesia.Metode: studi deskriptif, potong lintang, multisenter, dilakukan pada November 2008 sampai dengan November 2009. Tujuh puluh data pasien mieloma multipel diambil dari seluruh Indonesia, dari kelompok studi mieloma multipel di Indonesia.Hasil: Lebih dari enam puluh persen pasien mieloma multipel di Indonesia berusia lebih dari 50 tahun (65,71%) dengan perbadingan jenis kelamin yang kurang lebih sama antara pria dan wanita. Kurang lebih lima puluh persen pasien bersuku Jawa, dengan tingkat pendidikan Sekolah Menengah Atas (SMA) dan tidak bekerja.Lima puluh tiga persen pasien memiliki kurang dari 30% sel plasma di sumsum tulangnya dengan 70% pasien tidak memiliki proteinuria Bence Jones dan 80% pasien memiliki serum monoclonal gammopathy yang positif. Persentase sel plasma di sumsum tulang lebih banyak ditemukan pada pasien yang berusia lebih muda (34,05% vs. 24,24% vs. 7,5%). Dilaporkan bahwa hampir lima puluh persen pasien memiliki stadium IIIA berdasarkan klasifikasi Durie Salmon Staging system. Stadium penyakit yang lebih tinggi berkaitan dengan usia yang lebih tua berdasarkan klasifikasi International Myeloma Working Group. Melphalan/prednisone merupakan pilihan kemoterapi yang paling banyak digunakan (59,7%) dengan hasil pengobatan terbanyak adalah respons parsial.Kesimpulan: karakteristik pasien mieloma multipel di Indonesia didominasi oleh suku Jawa, dengan tingkat pendidikan SMA dan tidak bekerja. Sebagian besar pasien memiliki sel plasma kurang dari 30% di sumsum tulang, proteinuria Bence Jones yang negatif, dan serum monoclonal gammopathy yang positif. Hampir lima puluh persen pasien memiliki stadium IIIA dengan melphalan/prednison sebagai jenis kemoterapi terbanyak yang diberikan dengan hasil terbaik sebagian besar adalah respon parsial.Kata kunci: mieloma multipel, karakteristik klinis, Indonesia
Association of Clinical Features and Hematological Laboratoriesbetween Ph (+)/BCR-ABL (+) Chronic Myeloid Leukemia and Other Type of Ph/BCR-ABL Chronic Myeloid Leukemia Rajabto, Wulyo; Harryanto, A.; Tadjoedin, Hilman; Harimurti, Kuntjoro
Jurnal Penyakit Dalam Indonesia Vol. 5, No. 1
Publisher : UI Scholars Hub

Show Abstract | Download Original | Original Source | Check in Google Scholar

Abstract

Introduction. Patients with chronic phase Chronic Myeloid Leukemia (CML) at Hematology-Medical Oncology Clinic Department of Internal Medicine dr. Cipto Mangunkusumo National Hospital who haveperformed cytogenetic and RTPCR BCR-ABL examination showed: Ph (+)/BCR-ABL (+) CML and other type of Ph/BCR-ABL CML. This study aims to identify the clinical features and hematological laboratories of chronic phase CML, the proportion of Ph (+)/BCR-ABL (+) CML, and association of clinical features and hematological laboratories between Ph (+)/BCR-ABL (+) CML and other type of Ph/ BCR-ABL CML. Methods. This is a cross-sectional study. The samples were taken by consecutive method. We used Chi-square test and logistic regression analysis. Association between variables considered significant when p value <0.05. Results. There were 80 subjects with chronic phase CML. Mean of age was: 39.4 (standard deviation 13.1) years. The comparison of clinical features and hematological laboratories between Ph (+)/BCR-ABL (+) CML and other type of Ph/ 12 | Jurnal Penyakit Dalam Indonesia | Vol. 5, No. 1 | Maret 2018 Wulyo Rajabto, A. Harryanto, Hilman Tadjoedin, Kuntjoro Harimurti BCR-ABL CML were: Symptomatic 80.6% : 100%; splenomegaly 82% : 92.3%; median of Hb 10,3 g/dL : 10,3 g/dL; median of white blood cell 124.620 : 127.050; median of thrombocyte 455.000 : 487.000. Bivariate and multivariate analysis showed no significant association of clinical features and hematological laboratories between Ph (+)/BCR-ABL (+) CML and other type of Ph/BCR-ABL CML. Conclusion. There was no significant association of clinical features and hematological laboratories between Ph (+)/BCRABL (+) CML and other type of Ph/BCR-ABL CML.
Characteristics and Survival of Patients with WHO Grade 4 Diffuse Glioma in Dharmais National Referral Cancer Hospital Tadjoedin, Hilman; Suryana, Kresna Dharma; Rosalina, Rosalina; Hartono, Bryan Arista; Widarta, Oskar Ady; Dewin, Nikrial; Andriani, Rini
Indonesian Journal of Cancer Vol 18, No 3 (2024): September
Publisher : http://dharmais.co.id/

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.33371/ijoc.v18i3.1261

Abstract

Background: The WHO grade 4 diffuse glioma are extremely aggressive and account for over 60% of adult Central Nervous System (CNS) tumors. The diagnosis and management pose significant challenges due to the need for comprehensive evaluation and holistic treatment approaches. This study aims to determine the clinical characteristics of WHO grade 4 diffuse glioma in Indonesia and the overall survival as a secondary goal. Methods: This is a retrospective cohort study of all WHO grade 4 glioma patients from 2017 to 2022 at Dharmais National Cancer Hospital, Jakarta, Indonesia. Demographic characteristics were presented descriptively. Kaplan-Meier plot was used to evaluate the median survival. Results: Twenty-eight patients were eligible for this study. The median age group is 45 years old, with equal male and female prevalence. Headache was the most prevalent primary symptom. The therapy following surgery was radiotherapy (RT) with chemosensitizer (82.1%) and RT alone (14.3%) with both followed by adjuvant chemotherapy. There was one patient (3.6%) underwent palliative therapy. The median survival of all patients was 10 months, whereas 10 months in RT with the chemo-sensitizer group and 1 month in RT only group. There was no statistically significant difference between RT with and without chemotherapy sensitizer in terms of survival rates. Conclusions: Our study reports a younger median age of WHO Grade 4 diffuse glioma. Male subjects were equivalent to females. Median OS was 10 months and were longer in RT with the chemosensitizer group. Further multicentered and at the genetic level investigation was needed, to achieve optimal outcomes.
Adult Hodgkin’s Lymphoma in Indonesian National Cancer Center Hospital: An Observational Study Tadjoedin, Hilman
Indonesian Journal of Cancer Vol 18, No 4 (2024): December
Publisher : http://dharmais.co.id/

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.33371/ijoc.v18i4.1273

Abstract

Background: Hodgkin’s lymphoma (HL) is a malignancy of lymphatic glands whose incidence is higher in Asia than in other continents and it is highly curable amongst other hematological malignancies. Our study aims to establish distribution data among HL patients in the Indonesian National Cancer Hospital.Method: A cohort retrospective was conducted from 2017 to 2021 on HL patients. Data on demographic and clinical characteristics were collected and described.Result: From 177 HL subjects, 52.5% were men with a median age of 32 years. B-symptoms occurred in 30.1% of subjects. Most subjects have great performance status (44%) and normal body mass index (39.6%). Comorbidities found were diabetes mellitus (10.3%) and hypertension (8.1%). By hematological examination, lactate dehydrogenase (LDH) level was found 85.7% more than 240 U/dL, hemoglobin (Hb) level 71.6% non-anemic, leukocytosis in 33.5%, and thrombocytosis in 59.4%. The disease stage is mostly in stage 2 (51%), with 19.2% having extra nodal lesions which are commonly found in bone marrow (32.2%). The outcome showed that 69.2% of subjects survived.Conclusion: In general, the majority of subjects were young adult males, with no B-symptoms, great performance status, no comorbidity, elevated LDH levels, normal Hb and white blood cell counts, high platelet counts, and were diagnosed with stage 2 disease. Most patients with Hodgkin’s Lymphoma survived for 5 years.
Epidemiology Profile of Stage IV Ovarian Cancer in Dharmais National Cancer Hospital: An Observational Study Tadjoedin, Hilman; Suryana, Kresna Dharma; Hanafi, Widyorini Lestari Hutami; Kunigara, Manika Putri; Shiba, Alyssa Fairudz
Indonesian Journal of Cancer Vol 19, No 1 (2025): March
Publisher : http://dharmais.co.id/

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.33371/ijoc.v19i1.1308

Abstract

Background: Stage IV ovarian cancer showed a low 5-year survival rate, around 31%. Regrettably, the unclear symptoms and the ineffectiveness of early detection result in many patients being diagnosed with stage IV. Moreover, establishing a stage IV diagnosis is challenging and tricky. This study aims to provide a comprehensive overview of the clinical, laboratory, histopathological, and survival characteristics of stage IV ovarian cancer patients.Method: A cross-sectional study with a descriptive observational design, 100 of 1520 subjects gathered from the Cancer Registry of Dharmais National Cancer Hospital between January 2018 and December 2022, conducted on stage IV ovarian cancer patients who were not accompanied by primary cancer at other sites.Results: Among the 100 study subjects, 76.0% were aged 40–60 years, with a median age of 49.5 years. Most had a normal nutritional status (39.0%) or were underweight (34.0%). Comorbidities were present in 40.0% of the subjects, with hypertension being the most common (57.5%). The initial symptoms were abdominal enlargement in 74.0% of subjects, with 43.0% reporting shortness of breath. Laboratory examinations revealed that the majority had hemoglobin levels 10 mg/dL (90.0%), serum creatinine levels 1.2 mg/dL (90.0%), and D-Dimer levels 2000 ng/ mL (69.0%). Histopathological analysis identified high-grade serous carcinoma (HGSC) in 24.0% and clear cell carcinoma in 19.0% of subjects. The most common metastatic sites were the pleura (44.0%), liver (41.0%), and lungs (25.0%). Around 48.0% and 41.0% had surgery only and surgery with adjuvant chemotherapy, respectively. The majority of the outcomes (91.0%) indicated that patients with stage IV ovarian cancer did not survive and the median survival among the subjects was 4 months.Conclusion: The majority of stage IV ovarian cancer patients were aged 40–60 years, with abdominal enlargement as the initial symptoms, elevated D-Dimer levels, HGSC as the predominant histopathological type, and a high mortality rate as the outcome. Further research is recommended to explore additional variables and analyze factors contributing to mortali
Factor Associated with Mortality of Hospitalized Cancer Patients with COVID-19 Infection in Indonesia National Cancer Center Kurniawati, Sri Agustini; Sutandyo, Noorwati; Tadjoedin, Hilman; Pradipta, Jaka; Ismuha, Ratu Ralna; Ummah, Citra Dovina Khaira; Suryana, Kresna Dharma; Budi, Erwin
Indonesian Journal of Cancer Vol 18, No 2 (2024): June
Publisher : http://dharmais.co.id/

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.33371/ijoc.v18i2.1077

Abstract

Background: Cancer patients with COVID-19 are at risk of developing severe complications and outcomes due to immunosuppressive and inflammatory states. This study aims to provide insight into risk factors associated with mortality in this population. Methods: A retrospective cohort study was conducted at Dharmais National Cancer Center, Jakarta, Indonesia, from May 2020 to July 2021. Data were collected through electronic medical records using the consecutive sampling technique. The numerical and categorical data were then tested statistically. Results: The results showed 180 cancer patients with COVID-19 were hospitalized at Dharmais National Cancer Center. Among the patients, 114 patients survived, and 66 patients deceased. Across all risk factors analyzed to mortality, patients with Diabetes Mellitus (OR 0.41;0.22-0.77, p-value 0.05) and high level of D-dimer (OR 2.00;1.06-3.79, P-value 0.05) have a higher risk in mortality. The Results showed that survived patients have lower D-dimer levels (2010 ng/L) and deceased patients have higher D-dimer levels (3264 ng/L) with P-value 0.05. Conclusion: High D-dimer levels and diabetes are risk factors significantly associated with mortality in hospitalized cancer patients with COVID-19 Infection.
Co-Authors A. Harryanto Abidin Widjanarko Arif Harryanto Reksodiputro, Arif Harryanto Arry Harryanto Reksodiputro, Arry Harryanto Aru W. Sudoyo Asrul Harsal, Asrul Bambang Karsono Budi, Erwin Dewin, Nikrial Djumhana Atmakusuma, Djumhana Dody Ranuhardy, Dody Hanafi, Widyorini Lestari Hutami Harryanto Reksodiputro, Harryanto Harryanto, A. Hartono, Bryan Arista Ikhwan Rinaldi Karmel L. Tambunan Kunigara, Manika Putri Kuntjoro Harimurti Noorwati S -, Noorwati S Noorwati Sutandyo Nugroho Prayogo Pradipta, Jaka Ratu Ralna Ismuha Rini Andriani Ronald Hukom Rosalina Rosalina Shiba, Alyssa Fairudz Shufrie Effendi, Shufrie Sri Agustini Kurniawati, Sri Agustini Suryana, Kresna Dharma Syafrizal Syafei, Syafrizal Toman Toruan, Toman Ummah, Citra Dovina Khaira Widarta, Oskar Ady Wulyo Rajabto Zakifman Jack, Zakifman Zubairi Djoerban